Based on this study, a phase I/II clinical trial was conducted to confirm the efficacy of KIF20A-66 (KIF20A-10–66) peptide in immunotherapy for patients with advanced pancreatic cancer (clinical trial registration: UMIN-CTR, number UMIN000004919). This evidence concerns the gene KIF20A and familial pancreatic carcinoma.